Chi-Feng Tseng
Overview
Explore the profile of Chi-Feng Tseng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tseng C, Chen L, Wang H, Liu Y, Shiah S
Cancer Sci
. 2022 Mar;
113(5):1601-1612.
PMID: 35253323
Sorafenib is a multikinase inhibitor for the standard treatment of advanced liver cancer patients. However, acquired resistance to sorafenib is responsible for a poor prognosis. Therefore, uncovering the molecular mechanisms...
2.
Lu Y, Tseng C, Lan B, Hsieh C
Materials (Basel)
. 2021 Nov;
14(22).
PMID: 34832345
In this study, hydrogen (H) and methane (CH) were used as reactive gases, and chemical vapor deposition (CVD) was used to grow single-layer graphene on a copper foil substrate. The...
3.
Chen H, Chang Y, Tseng C, Chiu C, Hong C, Wang W, et al.
Ann Surg Oncol
. 2017 Feb;
24(Suppl 3):685-686.
PMID: 28160139
No abstract available.
4.
Yeh Y, Cheng C, Yang S, Tseng C, Chang T, Tsai S, et al.
Oncotarget
. 2016 Dec;
8(3):5603-5618.
PMID: 27901498
Vascular endothelial growth factor-C (VEGF-C) has been implicated in epithelial-mesenchymal transition (EMT) processes and various human cancers, including skin cancer. Skin cancer is an aggressive human malignancy with increasing incidence...
5.
Chen H, Kuo T, Tseng C, Ma J, Yang S, Yen C, et al.
Hepatology
. 2016 Aug;
64(5):1637-1651.
PMID: 27530187
Conclusion: ANGPTL1 inhibits sorafenib resistance and cancer stemness in HCC cells by repressing EMT through inhibition of the MET receptor-AKT/ERK-Egr-1-Slug signaling cascade. ANGPTL1 may serve as a novel MET receptor...
6.
Chang Y, Chen H, Tseng C, Hong C, Ma J, Hung M, et al.
Oncotarget
. 2014 Oct;
5(21):10558-70.
PMID: 25301734
Elevated expression of heat shock protein 5 (HSPA5) promotes drug resistance and metastasis and is a marker of poor prognosis in breast cancer patients. Adenovirus type 5 E1A gene therapy...
7.
Chen H, Chang Y, Tseng C, Chiu C, Hong C, Wang W, et al.
Ann Surg Oncol
. 2014 Sep;
22(3):889-98.
PMID: 25212833
Background: Triple-negative breast cancer (TNBC) is defined by reduced expression of the estrogen receptor, progesterone receptor, and HER2. TNBC is an especially aggressive group of breast cancers with poor prognosis....
8.
Chen J, Su Y, Chiu C, Chang Y, Yu Y, Tseng C, et al.
Ann Surg Oncol
. 2014 Apr;
21 Suppl 4:S555-63.
PMID: 24723223
Background: Accumulating evidence is revealing an important role of microRNA (miRNA) in tumor progression and chemotherapeutic resistance. Dicer is a cytoplasmic endoribonuclease type III crucial for production of mature miRNAs....